Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study

BACKGROUND: Well-designed studies with sufficient sample size comparing andexanet alfa vs 4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate clinical outcomes are limited. OBJECTIVES: To compare in-hospital mortality in patients hospitalized with rivaroxaban-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobesh, Paul P., Fermann, Gregory J., Christoph, Mary J., Koch, Bruce, Lesén, Eva, Chen, Hungta, Lovelace, Belinda, Dettling, Theresa, Danese, Mark, Ulloa, Julie, Danese, Sherry, Coleman, Craig I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518480/
https://www.ncbi.nlm.nih.gov/pubmed/37753225
http://dx.doi.org/10.1016/j.rpth.2023.102192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518480/
https://www.ncbi.nlm.nih.gov/pubmed/37753225
http://dx.doi.org/10.1016/j.rpth.2023.102192

Ejemplares similares